5(6)-ROX (5-(and-6)-Carboxy-X-rhodamine)

Product Description

5(6)-ROX (5-(and-6)-Carboxy-X-rhodamine)
Catalog number: B2011362
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 25 mg
Molecular Weight or Concentration: 534.6 g/mol
Supplied as: Lyophilized
Applications: molecular tool for various biochemical applications
Storage: -20 °C
Keywords: 5-(and-6)-Carboxy-X-rhodamine
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, García-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High-Flow Therapy Am J Respir Crit Care Med. 2019 Jun 1;199(11):1368-1376.
2: SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, Auchus AP, Bryan RN, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Erus G, Fine LJ, Gaussoin SA, Harris D, Hsieh MK, Johnson KC, Kimmel PL, Tamura MK, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nasrallah IM, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT Jr, Wright CB. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: A Randomized Clinical Trial JAMA. 2019 Feb 12;321(6):553-561.
3: ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Mackle D, Bellomo R, Bailey M, Beasley R, Deane A, Eastwood G, Finfer S, Freebairn R, King V, Linke N, Litton E, McArthur C, McGuinness S, Panwar R, Young P; ICU-ROX Investigators the Australian and New Zealand Intensive Care Society Clinical Trials Group. Conservative Oxygen Therapy during Mechanical Ventilation in the ICU N Engl J Med. 2020 Mar 12;382(11):989-998.
4: Panadero C, Abad-Fernández A, Rio-Ramirez MT, Acosta Gutierrez CM, Calderon-Alcala M, Lopez-Riolobos C, Matesanz-Lopez C, Garcia-Prieto F, Diaz-Garcia JM, Raboso-Moreno B, Vasquez-Gambasica Z, Andres-Ruzafa P, Garcia-Satue JL, Calero-Pardo S, Sagastizabal B, Bautista D, Campos A, González M, Grande L, Jimenez Fernandez M, Santiago-Ruiz JL, Caravaca Perez P, Alcaraz AJ. High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 Multidiscip Respir Med. 2020 Sep 16;15(1):693.
5: Hu M, Zhou Q, Zheng R, Li X, Ling J, Chen Y, Jia J, Xie C. Application of high-flow nasal cannula in hypoxemic patients with COVID-19: a retrospective cohort study BMC Pulm Med. 2020 Dec 24;20(1):324.
6: SPRINT MIND Investigators for the SPRINT Research Group, Nasrallah IM, Pajewski NM, Auchus AP, Chelune G, Cheung AK, Cleveland ML, Coker LH, Crowe MG, Cushman WC, Cutler JA, Davatzikos C, Desiderio L, Doshi J, Erus G, Fine LJ, Gaussoin SA, Harris D, Johnson KC, Kimmel PL, Kurella Tamura M, Launer LJ, Lerner AJ, Lewis CE, Martindale-Adams J, Moy CS, Nichols LO, Oparil S, Ogrocki PK, Rahman M, Rapp SR, Reboussin DM, Rocco MV, Sachs BC, Sink KM, Still CH, Supiano MA, Snyder JK, Wadley VG, Walker J, Weiner DE, Whelton PK, Wilson VM, Woolard N, Wright JT Jr, Wright CB, Williamson JD, Bryan RN. Association of Intensive vs Standard Blood Pressure Control With Cerebral White Matter Lesions JAMA. 2019 Aug 13;322(6):524-534.
7: Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, Rump LC, Persu A, Basile J, Bloch MJ, Daemen J, Lobo MD, Mahfoud F, Schmieder RE, Sharp ASP, Weber MA, Sapoval M, Fong P, Pathak A, Lantelme P, Hsi D, Bangalore S, Witkowski A, Weil J, Kably B, Barman NC, Reeve-Stoffer H, Coleman L, McClure CK, Kirtane AJ; RADIANCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial Lancet. 2021 Jun 26;397(10293):2476-2486.
8: Young P, Mackle D, Bellomo R, Bailey M, Beasley R, Deane A, Eastwood G, Finfer S, Freebairn R, King V, Linke N, Litton E, McArthur C, McGuinness S, Panwar R; ICU-ROX Investigators the Australian New Zealand Intensive Care Society Clinical Trials Group. Conservative oxygen therapy for mechanically ventilated adults with sepsis: a post hoc analysis of data from the intensive care unit randomized trial comparing two approaches to oxygen therapy (ICU-ROX) Intensive Care Med. 2020 Jan;46(1):17-26.
9: Gianstefani A, Farina G, Salvatore V, Alvau F, Artesiani ML, Bonfatti S, Campinoti F, Caramella I, Ciordinik M, Lorusso A, Nanni S, Nizza D, Nava S, Giostra F. Role of ROX index in the first assessment of COVID-19 patients in the emergency department Intern Emerg Med. 2021 Oct;16(7):1959-1965.
10: Leung K. Galactosamine-serum albumin-rhodamineX(20) 2007 Dec 10 [updated 2008 Jan 18]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013.

Products Related to 5(6)-ROX (5-(and-6)-Carboxy-X-rhodamine) can be found at Fluorescence